Vantage logo

Aldeyra eyes the future

A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.

Vantage logo

Persistence pays off for Kala

The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.

Vantage logo

Clearside’s future clouds over

After failing in retinal vein occlusion, the prospects for the eye project Xipere – and Clearside Biomedical itself – hinge on the smaller uveitis indication.